293 related articles for article (PubMed ID: 37400520)
1. Identification of cuproptosis-related lncRNA for predicting prognosis and immunotherapeutic response in cervical cancer.
Kong X; Xiong Y; Xue M; He J; Lu Q; Chen M; Li L
Sci Rep; 2023 Jul; 13(1):10697. PubMed ID: 37400520
[TBL] [Abstract][Full Text] [Related]
2. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
3. Signature of seven cuproptosis-related lncRNAs as a novel biomarker to predict prognosis and therapeutic response in cervical cancer.
Liu X; Zhou L; Gao M; Dong S; Hu Y; Hu C
Front Genet; 2022; 13():989646. PubMed ID: 36204323
[No Abstract] [Full Text] [Related]
4. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer.
Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y
BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429
[TBL] [Abstract][Full Text] [Related]
6. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.
Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S
Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774
[TBL] [Abstract][Full Text] [Related]
7. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
9. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
10. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
11. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
12. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
[TBL] [Abstract][Full Text] [Related]
13. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia.
Zhu Y; He J; Li Z; Yang W
BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692
[TBL] [Abstract][Full Text] [Related]
14. Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis.
Li H; Jiang H; Huang Z; Chen Z; Chen N
Aging (Albany NY); 2023 Aug; 15(16):8325-8344. PubMed ID: 37616061
[TBL] [Abstract][Full Text] [Related]
15. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract][Full Text] [Related]
16. Characterization of cuproptosis-related lncRNA landscape for predicting the prognosis and aiding immunotherapy in lung adenocarcinoma patients.
Sun X; Song J; Lu C; Sun X; Yue H; Bao H; Wang S; Zhong X
Am J Cancer Res; 2023; 13(3):778-801. PubMed ID: 37034212
[TBL] [Abstract][Full Text] [Related]
17. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
Bai Y; Zhang Q; Liu F; Quan J
Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
[TBL] [Abstract][Full Text] [Related]
18. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
19. Identification of cuproptosis-related long noncoding RNA signature for predicting prognosis and immunotherapy response in bladder cancer.
Huang G; Huang Y; Zhang C; Jiang Y; Ye Z; He C; Yu F; Chen Z; Xi X
Sci Rep; 2022 Dec; 12(1):21386. PubMed ID: 36496537
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
